
Reset all filters
01 3Lo Loestrin
02 1Myfembree
03 3Myfembree/Ryeqo
Main Therapeutic Indication : Urology
Currency : USD
2020 Revenue in Millions : 356
2019 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Urology
Currency : USD
2021 Revenue in Millions : 437
2020 Revenue in Millions : 356
Growth (%) : 23
Main Therapeutic Indication : Urology
Currency : USD
2019 Revenue in Millions : 589
2018 Revenue in Millions : 528
Growth (%) : 12
Main Therapeutic Indication : Women's Healthcare
Currency : USD
2021 Revenue in Millions : 8
2020 Revenue in Millions : 0
Growth (%) : New Launch in 2021
Main Therapeutic Indication : Women's Health
Currency : USD
2022 Revenue in Millions : 25
2021 Revenue in Millions : 8
Growth (%) : 234
Main Therapeutic Indication : Women's Health
Currency : USD
2023 Revenue in Millions : 60
2022 Revenue in Millions : 32
Growth (%) : 110
Relugolix, Estradiol, Norethisterone Acetate
Main Therapeutic Indication : Women?s Health
Currency : USD
2024 Revenue in Millions : 78
2023 Revenue in Millions : 67
Growth (%) : 16